FOXO Technologies Inc. (FOXO) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist FOXO Technologies Inc. (FOXO) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 63/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 17. März 2026FOXO Technologies Inc. (FOXO) Gesundheitswesen & Pipeline-Uebersicht
FOXO Technologies Inc. operates as a technology platform company, commercializing longevity science for the life insurance sector. Its FOXO Labs and FOXO Life platforms aim to streamline underwriting and enhance consumer engagement by integrating epigenetic biomarkers and proprietary insurance products, differentiating it within the healthcare information services industry.
Investmentthese
FOXO Technologies Inc. presents a unique investment opportunity within the healthcare information services sector, driven by its focus on integrating longevity science with the life insurance industry. The company's innovative approach to simplifying underwriting and enhancing consumer engagement through its FOXO Labs and FOXO Life platforms positions it for potential growth. A key value driver is the increasing demand for personalized and data-driven insurance solutions. The company's negative profit margin of -66.5% indicates it is still in a growth phase. Upcoming catalysts include potential partnerships with major life insurance carriers and the expansion of its epigenetic biomarker testing capabilities. However, investors should be aware of the risks associated with operating in a highly regulated industry and the challenges of scaling a technology-driven business in the insurance sector.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- FOXO Technologies Inc. operates in the healthcare information services sector, focusing on longevity science.
- The company's platforms, FOXO Labs and FOXO Life, aim to improve underwriting and consumer engagement in the life insurance industry.
- FOXO's gross margin stands at 46.7%, indicating potential for profitability as the company scales.
- The company was founded in 2019 and has 102 employees.
- The company has a beta of 2.59, indicating higher volatility compared to the market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Innovative technology platform integrating longevity science with life insurance.
- Proprietary epigenetic biomarker testing capabilities.
- Potential for strategic partnerships with major life insurance carriers.
- Focus on personalized and data-driven insurance solutions.
Schwaechen
- Limited operating history and small market capitalization.
- Negative profit margin and reliance on external funding.
- Dependence on regulatory approvals for its products and services.
- Competition from established players in the insurance and healthcare technology sectors.
Katalysatoren
- Upcoming: Potential partnerships with major life insurance carriers to integrate FOXO's technology into their underwriting processes.
- Upcoming: Expansion of FOXO Labs services to include additional epigenetic biomarkers and testing capabilities.
- Ongoing: Development and launch of proprietary life insurance products through the FOXO Life platform.
- Ongoing: Geographic expansion into new markets in North America, Europe, and Asia.
- Ongoing: Integration with corporate wellness programs and healthcare providers to offer proactive health assessments.
Risiken
- Potential: Regulatory changes and compliance requirements impacting the life insurance and healthcare industries.
- Potential: Technological obsolescence and competition from new entrants in the longevity science and insurance technology sectors.
- Potential: Economic downturn and reduced consumer spending on life insurance products.
- Ongoing: Data security and privacy concerns related to the collection and use of personal health information.
- Ongoing: Limited operating history and small market capitalization increasing investment risk.
Wachstumschancen
- Expansion of FOXO Labs Services: FOXO can grow by expanding the services offered through its FOXO Labs platform. This includes incorporating additional epigenetic biomarkers and developing more sophisticated underwriting protocols. The market for advanced underwriting solutions is estimated to reach $5 billion by 2028, presenting a significant opportunity for FOXO to capture market share. Success hinges on demonstrating the accuracy and reliability of its biomarker-based assessments.
- Strategic Partnerships with Life Insurance Carriers: Forming strategic partnerships with major life insurance carriers represents a substantial growth opportunity for FOXO. By integrating its technology into the carriers' existing underwriting processes, FOXO can gain access to a large customer base and accelerate adoption of its solutions. The life insurance market is valued at over $800 billion globally, providing ample room for growth through partnerships. These partnerships will be crucial for FOXO's market penetration and revenue generation.
- Development of Proprietary Life Insurance Products: FOXO has the opportunity to develop and launch its own proprietary life insurance products through its FOXO Life platform. These products can be designed to specifically leverage the insights gained from its epigenetic biomarker testing, offering personalized coverage options and enhanced customer engagement. The market for personalized insurance products is growing rapidly, driven by consumer demand for tailored solutions. FOXO's success in this area will depend on its ability to create innovative and competitive insurance offerings.
- Geographic Expansion: FOXO can expand its operations geographically, targeting new markets in North America, Europe, and Asia. The demand for longevity-focused healthcare solutions is growing globally, creating opportunities for FOXO to establish a presence in new regions. International expansion will require FOXO to adapt its products and services to meet local regulatory requirements and cultural preferences. This expansion could significantly increase FOXO's revenue and market reach.
- Integration with Wellness Programs: FOXO can integrate its technology with corporate wellness programs and healthcare providers to offer proactive health assessments and personalized recommendations. By providing individuals with insights into their biological age and potential health risks, FOXO can help them make informed decisions about their lifestyle and healthcare. The market for corporate wellness programs is expanding, driven by employers' desire to improve employee health and productivity. FOXO's integration with these programs could create a new revenue stream and enhance its brand awareness.
Chancen
- Expansion of FOXO Labs services and product offerings.
- Geographic expansion into new markets.
- Integration with corporate wellness programs and healthcare providers.
- Development of proprietary life insurance products.
Risiken
- Regulatory changes and compliance requirements.
- Technological obsolescence and competition from new entrants.
- Economic downturn and reduced consumer spending on life insurance.
- Data security and privacy concerns.
Wettbewerbsvorteile
- Proprietary technology platform that integrates longevity science with life insurance.
- Unique epigenetic biomarker testing capabilities through FOXO Labs.
- Strategic partnerships with life insurance carriers.
- First-mover advantage in the emerging market for longevity-focused insurance solutions.
Ueber FOXO
Founded in 2019 and based in Minneapolis, Minnesota, FOXO Technologies Inc. is a technology platform company focused on revolutionizing the life insurance industry through the application of longevity science. The company's core mission is to develop products and services that seamlessly integrate longevity science with life insurance offerings, thereby improving consumer health and wellness engagement while also simplifying the often complex and cumbersome underwriting process. FOXO operates through two primary platforms: FOXO Labs and FOXO Life. FOXO Labs is a services platform designed to incorporate saliva-based epigenetic biomarkers into accelerated underwriting protocols, aiming to provide a more efficient and customer-friendly underwriting experience. FOXO Life, on the other hand, is an insurance products platform that offers both proprietary life insurance products and third-party life insurance carrier products, all of which are based on the concept of bundling longevity science with life insurance. This approach allows FOXO to offer unique and innovative insurance solutions that cater to the evolving needs of consumers in the life insurance market. FOXO's technology aims to make life insurance more accessible and relevant to a broader audience.
Was das Unternehmen tut
- Develops a technology platform focused on longevity science.
- Integrates epigenetic biomarkers into life insurance underwriting.
- Offers saliva-based epigenetic testing through FOXO Labs.
- Provides proprietary and third-party life insurance products through FOXO Life.
- Aims to simplify the consumer underwriting journey.
- Enhances consumer health and wellness engagement.
Geschaeftsmodell
- Generates revenue through FOXO Labs by providing epigenetic biomarker testing services to life insurance companies.
- Earns revenue through FOXO Life by selling proprietary life insurance products.
- Collects fees from third-party life insurance carriers for offering their products on its platform.
- Partnerships with insurance companies to integrate FOXO's technology into their underwriting processes.
Branchenkontext
FOXO Technologies Inc. operates within the healthcare information services industry, a sector experiencing rapid growth due to technological advancements and increasing demand for personalized healthcare solutions. The integration of data analytics and AI in healthcare is transforming traditional practices, creating opportunities for companies like FOXO to innovate. The competitive landscape includes established players in the insurance and healthcare technology sectors, as well as emerging companies focused on longevity science. FOXO's unique approach of combining epigenetic biomarkers with life insurance products differentiates it from competitors. The market for personalized insurance solutions is expanding, driven by consumer demand for tailored products and services.
Wichtige Kunden
- Life insurance companies seeking to improve their underwriting processes.
- Consumers interested in personalized life insurance products based on longevity science.
- Healthcare providers looking to offer proactive health assessments to their patients.
- Corporate wellness programs seeking to enhance employee health and well-being.
Finanzdaten
Chart & Info
FOXO Technologies Inc. (FOXO) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
12 Information Technology Stocks Moving In Tuesday's After-Market Session
benzinga · 6. Mai 2025
-
Crude Oil Rises Sharply; US Trade Deficit Widens In March
benzinga · 6. Mai 2025
-
12 Information Technology Stocks Moving In Thursday's Intraday Session
benzinga · 17. Apr. 2025
-
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
benzinga · 11. Nov. 2024
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer FOXO.
Kursziele
Wall-Street-Kurszielanalyse fuer FOXO.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von FOXO auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
Aktuelle Nachrichten
12 Information Technology Stocks Moving In Tuesday's After-Market Session
Crude Oil Rises Sharply; US Trade Deficit Widens In March
12 Information Technology Stocks Moving In Thursday's Intraday Session
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Fuehrung: Seamus Lagan
CEO
Seamus Lagan is the CEO of FOXO Technologies Inc. His background includes experience in managing and scaling technology-driven companies. He has a proven track record in strategic leadership and business development. Lagan's expertise lies in driving innovation and commercializing new technologies. He is responsible for overseeing the company's overall strategy and operations. His leadership is focused on executing FOXO's vision of transforming the life insurance industry through longevity science.
Erfolgsbilanz: Under Seamus Lagan's leadership, FOXO Technologies Inc. has focused on developing its FOXO Labs and FOXO Life platforms. Key milestones include the integration of epigenetic biomarkers into underwriting protocols and the launch of proprietary life insurance products. Lagan has been instrumental in securing partnerships and driving the company's growth strategy. His focus on innovation and customer engagement has positioned FOXO for success in the evolving life insurance market.
FOXO OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that FOXO Technologies Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, which increases investment risk. Trading on the OTC Other tier typically involves less stringent listing requirements compared to exchanges like the NYSE or NASDAQ, resulting in a higher degree of speculative activity and potential for price volatility.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency.
- Higher potential for fraud and manipulation.
- Lower trading volume and liquidity.
- Greater price volatility.
- Increased risk of delisting or suspension of trading.
- Verify the company's registration and regulatory filings.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Company has a registered business address and contact information.
- Company has a functioning website and social media presence.
- Company has a management team with relevant experience.
- Company has a clear business plan and revenue model.
- Company has received positive media coverage or industry recognition.
Haeufige Fragen zu FOXO
What are the key factors to evaluate for FOXO?
FOXO Technologies Inc. (FOXO) currently holds an AI score of 63/100, indicating moderate score. Key strength: Innovative technology platform integrating longevity science with life insurance.. Primary risk to monitor: Potential: Regulatory changes and compliance requirements impacting the life insurance and healthcare industries.. This is not financial advice.
How frequently does FOXO data refresh on this page?
FOXO prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven FOXO's recent stock price performance?
Recent price movement in FOXO Technologies Inc. (FOXO) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative technology platform integrating longevity science with life insurance.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider FOXO overvalued or undervalued right now?
Determining whether FOXO Technologies Inc. (FOXO) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying FOXO?
Before investing in FOXO Technologies Inc. (FOXO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding FOXO to a portfolio?
Potential reasons to consider FOXO Technologies Inc. (FOXO) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Innovative technology platform integrating longevity science with life insurance.. Additionally: Proprietary epigenetic biomarker testing capabilities.. The AI-driven MoonshotScore of 63/100 reflects solid quantitative fundamentals. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of FOXO?
Yes, most major brokerages offer fractional shares of FOXO Technologies Inc. (FOXO) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track FOXO's earnings and financial reports?
FOXO Technologies Inc. (FOXO) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for FOXO earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Financial data is limited due to the company's OTC listing and disclosure status.
- AI analysis is pending, so analyst consensus is unavailable.